Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

Jonathan Canaani, MD, Marlise R. Luskin, MD, Alison Loren, MD MS, Colleen Timlin, PharmD, BCOP, James Mangan, MD PhD, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, David L Porter, MD, Edward A. Stadtmauer, MD, Selina Luger, MD

Blood (2015) 126 (23): 2543.

https://doi.org/10.1182/blood.V126.23.2543.2543

Published: 2015

Journal Articles

A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis

Gautam Borthakur, MD, James M. Foran, MD, Eunice S. Wang, MD, Amol Rakkar, Steven Hager, DO, Noelle V. Frey, MDMS, Michael Andreeff, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Bing Z Carter, PhD, Hans Minderman, Lesley Russell, Raoul Tibes, MD PhD

Blood (2014) 124 (21): 3263.

https://doi.org/10.1182/blood.V124.21.3263.3263

Published: 2014

Journal Articles

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Blood (2014) 124 (21): 3087.

https://doi.org/10.1182/blood.V124.21.3087.3087

Published: 2014

Journal Articles

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

Jingmei Hsu, MD PhD, Anita J. Kumar, MDMS, Martin P. Carroll, MD, Noelle V. Frey, MDMS, Nirav N. Shah, MD, Zhao Jianhua, PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, James K. Mangan, MDPhD, Alexander E. Perl, MD, David Porter, MD, Jennifer Morrissette, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 2343.

https://doi.org/10.1182/blood.V124.21.2343.2343

Published: 2014

Journal Articles

Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study

Ran Reshef, MD, James K. Mangan, MDPhD, Selina M. Luger, MD, Alison Wakoff Loren, MDMS, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, Edward A. Stadtmauer, MD, Robin E. Blauser, BSN RN, Lee P. Richman, BA, Austin P. Huffman, BA, Alex Ganetsky, PharmD, Edward P. Acosta, PharmD, James A. Hoxie, MD, Rosemarie Mick, MS, Robert H. Vonderheide, MDDPhil, David L. Porter, MD

Blood (2014) 124 (21): 2491.

https://doi.org/10.1182/blood.V124.21.2491.2491

Published: 2014

Journal Articles

Provider Based Outcomes on an Allogeneic Transplant Service

Nirav N. Shah, MD, Colleen Kucharczuk, CRNP, Nandita Mitra, PhD, Rebecca Hirsh, MD, Jakub Svoboda, MD, David Porter, MD, Alison W. Loren, MDMS, Noelle V. Frey, MDMS, Marilyn M. Schapira, MD MPH

Blood (2014) 124 (21): 2643.

https://doi.org/10.1182/blood.V124.21.2643.2643

Published: 2014

Journal Articles

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

Alexis Zebrowski, BA, Alexandra Hanlon, PhD, James Mangan, MD PhD, Jennifer Pinto-Martin, PhD MPH, Selina M. Luger, MD, Alison W. Loren, MD, Elizabeth O Hexner, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 1239.

https://doi.org/10.1182/blood.V124.21.1239.1239

Published: 2014

Journal Articles

CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation

Ran Reshef, MD, Austin P. Huffman, BA, Amy Gao, BA, Mary Sell, BS MT(ASCP), Marlise R. Luskin, MD, Selina M. Luger, MD, Alison Wakoff Loren, MDMS, Elizabeth O. Hexner, MD, Sunita Dwivedy Nasta, MD, Noelle V. Frey, MDMS, Saar I. Gill, MD PhD, James Mangan, MD PhD, Lee P. Richman, BA, Taku Kambayashi, MDPhD, Edward A. Stadtmauer, MD, Robert H. Vonderheide, MDDPhil, David L. Porter, MD

Blood (2014) 124 (21): 1260.

https://doi.org/10.1182/blood.V124.21.1260.1260

Published: 2014

Journal Articles

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Blood (2014) 124 (21): 1982.

https://doi.org/10.1182/blood.V124.21.1982.1982

Published: 2014

Journal Articles

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Blood (2014) 124 (21): 1983.

https://doi.org/10.1182/blood.V124.21.1983.1983

Published: 2014

Journal Articles

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

Noelle V. Frey, MDMS, Bruce L. Levine, PhD, Simon F. Lacey, PhD BSc, Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Stephen J. Schuster, MD, Pamela Shaw, PhD, Wei-Ting Hwang, PhD, Mariusz A. Wasik, MD, Amrom Obstfeld, MD, Mimi Leung, MPH, Angela Shen, MD, Solveig G. Ericson, MD PhD, Jan J Melenhorst, PhD, Carl H. June, MD, David Porter, MD

Blood (2014) 124 (21): 2296.

https://doi.org/10.1182/blood.V124.21.2296.2296

Published: 2014

Journal Articles

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Noelle V. Frey, MDMS, Selina Luger, MD, James Mangan, MD PhD, Alexis Zebrowski, BA, Alison W. Loren, MDMS, Hans Minderman, John Baird, MD, David L Porter, MD, Elizabeth O. Hexner, MD, Anita J. Kumar, MDMS, Marlise R. Luskin, MD, Alexander E Perl, MD, Martin Carroll, MD

Blood (2014) 124 (21): 3758.

https://doi.org/10.1182/blood.V124.21.3758.3758

Published: 2014

Journal Articles

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Anita J. Kumar, MDMS, Pavel Vassilev, BS, Alison W. Loren, MDMS, Selina M. Luger, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Steven C. Goldstein, MD, Elizabeth Hexner, MD, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 3946.

https://doi.org/10.1182/blood.V124.21.3946.3946

Published: 2014

NARROW

Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy

A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study

Provider Based Outcomes on an Allogeneic Transplant Service

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only